Episodio – Mutación KRAS y resistencia a terapias anti-EGFR | USMLE Step 1

from USMLE DREAMERS · host USMLE DREAMERS

Paciente con cáncer colorrectal metastásico y anemia microcítica. Revisamos el eje EGFR–KRAS, por qué ciertos tumores responden a anticuerpos monoclonales como cetuximab/panitumumab, y cómo una mutación activadora en KRAS genera resistencia terapéutica. Alta integración entre oncología molecular, señalización celular y terapias dirigidas.#USMLE #Step1 #Oncologia #KRAS #EGFR #Cetuximab #Panitumumab #ColonCancer #USMLEDreamers #MolecularTargets #TargetedTherapy

What this episode covers

NOW PLAYING

0:00 6:02

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of USMLE DREAMERS?

This episode is 6 minutes long.

When was this USMLE DREAMERS episode published?

This episode was published on November 28, 2025.

What is this episode about?

Can I download this USMLE DREAMERS episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.

URL copied to clipboard!